Small dense LDL particles - a predictor of coronary artery disease evaluated by invasive and CT-based techniques: a case-control study by Toft-Petersen, Anne P et al.
RESEARCH Open Access
Small dense LDL particles - a predictor of
coronary artery disease evaluated by invasive
and CT-based techniques: a case-control study
Anne P Toft-Petersen
1, Hans H Tilsted
1, Jens Aarøe
1, Klaus Rasmussen
1, Thorkil Christensen
2, Bruce A Griffin
3,
Inge V Aardestrup
1, Annette Andreasen
1, Erik B Schmidt
1*
Abstract
Background: Coronary angiography is the current standard method to evaluate coronary atherosclerosis in
patients with suspected angina pectoris, but non-invasive CT scanning of the coronaries are increasingly used for
the same purpose.
Low-density lipoprotein (LDL) cholesterol and other lipid and lipoprotein variables are major risk factors for
coronary artery disease. Small dense LDL particles may be of particular importance, but clinical studies evaluating
their predictive value for coronary atherosclerosis are few.
Methods: We performed a study of 194 consecutive patients with chest pain, a priori considered of low to
intermediate risk for significant coronary stenosis (>50% lumen obstruction) who were referred for elective
coronary angiography. Plasma lipids and lipoproteins were measured including the subtype pattern of LDL
particles, and all patients were examined by coronary CT scanning before coronary angiography.
Results: The proportion of small dense LDL was a strong univariate predictor of significant coronary artery stenosis
evaluated by both methods. After adjustment for age, gender, smoking, and waist circumference only results
obtained by traditional coronary angiography remained statistically significant.
Conclusion: Small dense LDL particles may add to risk stratification of patients with suspected angina pectoris.
Introduction
Coronary artery disease (CAD) is a common cause of
morbidity and mortality in the industrialised world [1].
The diagnosis of coronary atherosclerosis is usually
made by invasive coronary angiography (CAG) during
which percutaneous coronary intervention (PCI) proce-
dures can be applied simultaneously. CAG is invasive,
exposes the patient to a moderate amount of radiation
and iodinated contrast agent, and depicts only athero-
sclerotic lesions that bulge into the lumen. Among the
currently available non-invasive alternatives, CT-based
coronary angiography (CT CAG) provides a view of the
vessel lumen as well as the architecture of the vessel
wall. Additionally, the degree of calcification, which has
been shown to be a prognostic marker for CAD [2], can
be accessed. Disadvantages of CT CAG include the rela-
tively large dose of radiation, the inability to perform
intervention, and inconclusive scans. Equipment for CT
CAG is, however, being improved, and presumably this
will reduce the failure rate and lead to a lower dose of
radiation. CT CAG, measured with invasive CAG as the
golden standard, offers a high sensitivity for coronary
stenoses, whereas the specificity is moderate [3]. It has
therefore been argued that patients at low or moderate
risk of CAD should undergo a “screening” CT CAG that
could select patients for possible intervention.
An elevated concentration of LDL cholesterol is a
major risk factor for CAD [4-6]. However, LDL consists
of a heterogeneous spectrum of particles with highly
variable atherogenic potential [7]. Small dense LDL par-
ticles (sdLDL) are believed to be particularly atherogenic
due to increased susceptibility to oxidation [8,9], high
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affinity [11], and an increased interaction with matrix
components [5].
The main hypothesis to be tested was that sdLDL
might be a better predictor of coronary atherosclerosis
than standard lipids and lipoproteins. Furthermore, we
evaluated levels of apoprotein (apo) B and lipoprotein
(a) (Lp(a)) in patients with chest pain considered at low
or intermediate risk for CAD and investigated by CAG
and CT CAG.
Methods
We performed a case-control study of 194 consecutive
patients with low or intermediate risk of CAD, referred
for elective CAG (invasive CAG) at Aalborg Hospital
between June 2007 and December 2008. Causes of refer-
ral were angina pectoris or angina equivalent symptoms.
Based on information of previous history, current symp-
toms, and risk factors patients were categorized clini-
cally as having a high risk or a low to intermediate risk
of CAD. We carried out a CT CAG as well as an inva-
sive CAG in all patients. Based on this, we grouped the
patients in two parallel analyses, i.e. CAD/no CAD on
CAG and CAD/no CAD on CT CAG, thus allowing
parallel comparisons of sdLDL as a risk factor for CAD
measured by different, yet clinically relevant, diagnostic
modalities. Patients underwent a CT CAG and later, but
within the same week, an invasive CAG, unless they met
any of the following exclusion criteria:
￿ A prior diagnosis of CAD, verified by:
○ elevated myocardial enzymes
○ signs of myocardial ischemia in ECG either
spontaneously or during a stress test
○ significant stenoses in the coronary arteries
demonstrated in an earlier invasive CAG
○ ischemia demonstrated by myocardial perfu-
sion scintigraphy or stress echocardiography
￿ Invasive CAG referral due to defect cardiac valves,
cardiomyopathy, or cardiac arrhythmias
￿ Elevated serum creatinine
￿ Diabetes mellitus
￿ Known intolerance to contrast agents
￿ Inability to hold the breath for at least 10 s in con-
nection with the CT CAG
￿ Contraindications against intravenously adminis-
tered b-adrenoceptor-antagonists
￿ Age less than 40 years
￿ Lack of contraception in premenopausal women
Patient characteristics are given in Table 1. Of the 194
patients enrolled, 3 dropped out before blood sampling,
and 13 were excluded as diabetics. Of the 178 complet-
ing, non-diabetic participants, 16 had a technically
unacceptable CT CAG and were excluded from this
part of the study. Three patients had serum triglycerides
≥5 mmol/L, and as this interfered with the calculation
of LDL cholesterol, they were excluded from the LDL
cholesterol comparisons as well as the adjusted analyses.
CAG and CT CAG
On the day of the CT scan, venous blood samples
(50 mL) were drawn. Serum lipids (total cholesterol,
high-density lipoprotein (HDL) cholesterol, and triglycer-
ides) were measured by routine methods at the central
laboratory, and LDL cholesterol was calculated according
to the Friedewald formula. Serum samples for the mea-
surement of apo B, Lp(a), and highly sensitive (hs)CRP
were frozen at -80°C and analysed after all patients had
been included. Apo B was measured using antibody from
DAKO, Glostrup, Denmark, on an Advia 1650 from
Bayer Diagnostics, NY, US. Lp(a) was measured using an
ELISA kit from Mercodia, Uppsala, Sweden, while hsCRP
was measured by an immunoturbidimetric assay from
Randox Laboratories LtD, UK, on an Advia 1650.
EDTA plasma (K3-EDTA 1.6 mg/mL blood) for the
separation of LDL subfractions was stored at -80°C.
Table 1 Basic characteristics of the patients included in
the study
Variable n = 178
Age (mean and SD) 62.4
± 9.6
Gender (male) (%) 49.4%
Family disposition to ischemic heart disease (%) 52.8%
Current smoking (%) 21.3%
Lipid-lowering medication (%) 59.0%
Antihypertensive medication (%) 67.4%
Systolic blood pressure (mean and SD) 146.7
± 20.2
Diastolic blood pressure (mean and SD) 79.3
± 10.5
BMI (kg/m
2) (mean and SD) 26.9
4.0
Waist circumference (cm) (mean and SD) 96.3
11.8
Triglycerides (mmol/L) (mean and SD) 1.5
1.0
HDL cholesterol (mmol/L serum) (mean and SD) 1.6
0.5
LDL cholesterol (mmol/L serum) (mean and SD) (n = 175) 2.8
0.9
High sensitive CRP (mean and SD) 2.8
4.7
ApoB (g/L) (mean and SD) 0.9
0.2
Lp(a) (arb. units) (mean and SD) 361.1
435.5
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(Optiprep 60%, Axis-Schield PoC As, Oslo, Norway) was
prestained with Coomassie blue, underlayered beneath 9%
iodixanol and subjected to ultracentrifugation (2 1/2 h,
65,000 rpm 16ºC, (341,000 g) in a near vertical rotor
(Beckmann NVT65). A digital photograph of LDL subclass
profiles was analysed using Total Lab 1D gel-scan software
(Pharmacis, UK). The LDL subfraction pattern was char-
acterised based on the fractional (percentage) occurrence
of small dense particles (density >1.031 g/mL) and large,
buoyant particles (density <1.031 g/mL)[12]. The method
has previously been described in detail [13,14].
The technique applied for CT CAG has previously been
described by Achenbach et al [15]. The scans were con-
ducted on a General Electric 64 slice scanner (LightSpeed
VCT). The contrast agent was Jomeron
®, 400 mg iod/mL.
Scans were performed mainly as helical scans. Only
arteries with an estimated luminal diameter >1.5 cm were
examined, and stenoses were, as with CAG, considered
significant if they obstructed at least 50% of the lumen.
CAD was considered present if one or more vessels had a
significant luminal obstruction.
Invasive CAG as well as analyses of blood samples
were performed after the CT CAG examination and
blinded to the evaluation of this.
CAG was conducted according to the routine protocol
applied by our department and with standard equip-
ment. Only arteries with an estimated luminal diameter
>1.5 cm were examined, and stenoses were considered
significant if they obstructed at least 50% of the lumen.
CAD was considered present if one or more vessels had
a significant luminal obstruction.
All participants gave an informed, written statement of
consent. The study was approved by the regional ethical
committee and conducted according to the Declaration
of Helsinki.
Statistics
All statistical analyses were conducted in “R”,v e r s i o n
2.9.1. T-tests were used for comparisons of continuous
data. Equality of variances was tested and allowed for in
the t-tests, and Fisher’se x a c tt e s tw a sa p p l i e df o rc o m -
parisons of binary exposures. Parallel analyses were con-
ducted based on CAG and CT CAG, respectively, i.e.
the patients were stratified into “CAD” and “no CAD”
according to either and then compared with respect to
risk factors. To access the impact of sdLDL on presence
of CAD binary, logistic regression analyses were made
based on 10% increments in sdLDL, and a number of
possible confounders, i.e. age, gender, current smoking,
waist circumference, and LDL cholesterol, were inter-
changeably adjusted for. To ensure that no important
differences were overlooked all data were analysed as
median values as well and compared with the Wilcoxon
rank sum test (data not shown).
Results
Invasive CAG
When stratified by invasive CAG (Table 2), patients with
CAD were significantly more likely to be of male gender
and to receive lipid-lowering drugs. They had a larger waist
circumference, but no differences were observed as to age,
family disposition, antihypertensive medication, BMI, cur-
rent smoking, or blood pressure. Patients with CAD had
significantly higher triglyceride and lower HDL cholesterol
values, but did not significantly differ with respect to total
cholesterol, LDL cholesterol, hsCRP, Lp(a), or apoB.
As depicted in Figure 1, patients with CAD had a sig-
nificantly higher proportion of small dense LDL (means
50.1% and 40.0%, respectively; p < 0.001).
Unadjusted sdLDL was a significant predictor of pre-
sence of CAD verified by invasive CAG in a logistic
regression analysis (Table 3; Crude). Adjustment for age,
gender, current smoking, and waist circumference
(Adjustment 1) or adjustment for LDL cholesterol
(Adjustment 2) did not materially reduce the estimate.
CT CAG
Stratified according to CT CAG, the risk profiles of the
patients were slightly different (Table 2). Patients with
CAD were older, more likely to receive lipid-lowering
drugs, and had higher BMI and larger waist circumference.
No lipid parameters, total cholesterol, LDL cholesterol, and
triglycerides differed between patients with and without
CAD, apart from patients with CAD having higher HDL
cholesterol. Patients without and with CAD verified by CT
CAG differed significantly in proportions of sdLDL (means
39.5% and 45.8%, respectively; p = 0.029) (Figure 2).
Crude sdLDL was a significant predictor of presence
of CAD verified by invasive CAG in a logistic regression
(Table 4; Crude). Adjustment for age, gender, current
smoking, and waist circumference (Adjustment 1)
reduced the estimate and rendered the prediction insig-
nificant. Additional adjustment for LDL cholesterol
(Adjustment 2) reduced the estimate and abolished the
significance.
Discussion
The present study demonstrates that the proportion of
small dense LDL particles is as t r o n gu n i v a r i a t ep r e d i c -
tor of clinically significant coronary luminal stenosis
and, in this data set, as strong a predictor as HDL cho-
lesterol. In our linear models we did not adjust for HDL
cholesterol and triglycerides, it being in our opinion
meaningless, as the three parameters are intimately
metabolically linked.
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ferent techniques, has been emphasised in several inves-
tigations, among those the Quebec Cardiovascular Study
[16] in which men with an elevated sdLDL cholesterol
had a significantly higher risk of coronary heart disease
(CHD) on follow-up. Also in the EPIC-Norfolk study
[17], patients with coronary disease presented with a
smaller LDL peak particle size, a higher proportion of
sdLDL, and an increased plasma concentration of
sdLDL cholesterol than matched, healthy controls. Simi-
lar conclusions were drawn in a coinciding evaluation of
the same study population by El Harchaoui [18] who
reported a stronger association between the number of
sdLDL particles and occurrence of CAD, than between
serum LDL cholesterol and CAD. In accordance with
this finding, we saw no significant difference in LDL
cholesterol in groups with or without CAD, nor did
adjustment for LDL cholesterol influence the relation
between CAD and sdLDL particles, perhaps because the
patients included in the study deviated from the back-
ground population by an a priori moderately altered risk
profile and the use of statins.
Recognition of an intimate metabolic relationship
between triglycerides and other lipids has fuelled debate
as to which component is the principal marker of CVD
risk and has given rise to the description of a lipid phe-
notype consisting of a high proportion of small dense
LDL, high levels of triglycerides, and low concentrations
of HDL cholesterol [7] typical of patients with the meta-
bolic syndrome. Conversely, its degree of covariance
with other risk factors may help explain why the
strength of associations of these factors with CAD is
Table 2 Basic characteristics of patients, stratified according to presence of CAD verified by invasive CAG and
CT CAG, respectively
CAG CT CAG
Variable No CAD
(n = 120)
CAD
(n = 58)
p-value No CAD
(n = 71)
CAD
(n = 91)
p-value
Age (mean and SD)
T 61.6
± 9.8
64.1
± 8.9
0.1 60.4
± 9.8
64.1
± 8.9
0.02
Male (number and %)
F 46 (38.3) 42 (72.4) <0.0001 40.8 (29) 57.1 (52) 0.06
Family disposition to ischemic heart disease (number and %)
F 66 (55) 28 (48.3) 0.43 62.0 (44) 48.4 (44) 0.11
Actual smoking (number and %)
F 21 (17.5) 17 (29.3) 0.08 19.7 (14) 24.2 (22) 0.57
Lipid-lowering medication (number and %)
F 61 (50.8) 44 (75.9) 0.002 45.1 (32) 70.3 (64) 0.001
Antihypertensive medication (number and %)
F 75 (62.5) 45 (77.6) 0.06 62.0 (44) 71.4 (65) 0.24
Systolic blood pressure (mean and SD)
T 145.8
± 21.6
148.6
± 16.8
0.35 144.0
± 20.1
147.4
± 19.7
0.29
Diastolic blood pressure (mean and SD)
T 78.8
± 11.0
80.4
± 9.2
0.34 78.2
± 9.7
79.6
± 10.6
0.39
BMI (kg/m
2)(mean and SD)
T 26.7
± 4.3
27.2
± 3.1
0.4 25.9
± 4.0
27.4
± 3.9
0.02
Waist circumference (cm) (mean and SD)
T 94.8
± 12.4
99.6
± 9.7
0.005 92.8
± 11.9
98.1
± 11.4
<0.005
Total cholesterol (mmol/L) (mean and SD)
T 5.0
± 0.9
5.0
± 1.0
0.75 5.1
± 1.0
4.9
± 0.9
0.35
Triglycerides (mmol/L) (mean and SD)
T 1.3
0.7
1.8
1.3
0.02 1.3
0.7
1.2
0.8
0.1
HDL cholesterol (mmol/L ) (mean and SD)
T 1.7
0.5
1.4
0.4
<0.001 1.7
0.5
1.5
0.4
0.03
LDL cholesterol (mmol/L) (mean and SD)
T (ntotal = 175) 2.7
± 0.9
(n = 119)
2.8
± 0.8
(n = 56)
0.39 2.8
± 1.0
(n = 70)
2.7
± 0.8
(n = 89)
0.46
High sensitive CRP (mean and SD)
T 2.2
2.6
4.0
7.2
0.06 2.2
3.2
3.4
5.8
0.09
ApoB (g/L) (mean and SD)
T 0.9
± 0.2
1.0
± 0.2
0.09 0.9
± 0.2
0.9
± 0.2
0.91
Lp(a) (arb. units) (mean and SD)
T 315.1
387.9
456.4
511.0
0.06 276.5
346.2
412.9
487.4
0.07
sdLDL (mean and SD percentages)
T 40.0
16.8
50.1
19.5
<0.001 39.5
17.1
45.8
18.7
0.03
Numbers in parentheses. (CAG: n = 178 and CT CAG: n = 162 ) (F: Fisher’s exact test for count data, T: Students t-test, W: Wilcoxon rank sum test).
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with this, Austin et al. [19] found a significant, univariate
negative correlation between LDL size and CAD that van-
ished upon adjustment for HDL cholesterol, triglycerides,
and other traditional risk factors. In the Women’s Health
study [20], where LDL particle concentration was com-
pared to LDL particle size as risk predictors of coronary
mortality and morbidity, even the stronger of the two, the
particle concentration, was strongly attenuated by adjust-
ment. That sdLDL and LDL particle numbers are by no
means independent parameters has been illustrated by
Griffin et al. who reported that a predominance of sdLDL,
moderately elevated triglycerides, and a low HDL choles-
terol were all inversely associated with the number of LDL
particles [13].
In a case-control study of 225 middle-aged Japanese
CAD patients [21], Koba et al. found that the coronary
stenosis was highly correlated with an LDL particle dia-
meter less than 255 Å. The CAD patients had LDL
cholesterol and non-HDL cholesterol similar to healthy
controls, but sdLDL cholesterol was elevated. In a logistic
regression analysis, adjustment for HDL cholesterol
did, however, not abolish the effect of sdLDL cholesterol.
T h ep r e s e n ts t u d yd i f f e r sf r o mt h a ts t u d ym a i n l yi nt h e
measurement of the “sd” parameter (Kola et al. measured
cholesterol content whereas we measured the sdLDL
proportion) and in the recruitment of patients. Our
patients were enrolled based on a clinical suspicion of
CAD prior to enrolment, whereas in the study from
Japan, confirmed CAD patients were compared to
healthy controls who were younger and had a healthier
life style.
Kwon et al. [22] used a cross-sectional design to inves-
tigate the relation of LDL particle size to CAD. The
study population consisted of 504 patients without a
prior history of myocardial infarction who underwent a
CAG for evaluation of chest pain. Among these, 262
had at least one stenosis by CAG that obstructed 50% of
Table 3 Logistic regression analysis of CAD verified by
invasive CAG with proportions of sdLDL as exposure
(n = 175)
Odds ratio 95% CI P
Crude 1.36 1.13
1.64
0.001
Adjustment 1 1.26 1.02
1.56
<0.01
Adjustment 2 1.26 1.02
1.56
0.03
Odds ratios are expressed relative to sdLDL increments of 10%. (Adjusted 1:
age, gender, current smoking, waist circumference; adjusted 2: age, gender,
current smoking, waist circumference, LDL cholesterol).
Figure 1 Proportion of small dense LDL stratified according to
presence of CAD verified by invasive CAG. (n = 178; lines mean
mean ± sd). The mean proportions were 40.0% and 50.1%,
respectively.
Figure 2 Proportion of small dense LDL, stratified according to
presence of CAD verified by CT CAG. (n = 162; lines mean
mean ± sd). The proportions were 39.5% and 45.8%, respectively.
Table 4 Logistic regression analysis of CAD verified by CT
CAG with proportions of sdLDL as exposure (n = 159)
Odds ratio 95% CI P
Crude 1.26 1.03
1.53
0.02
Adjusted 1 1.20 0.96
1.50
0.11
Adjusted 2 1.21 0.97
1.52
0.09
Odds-ratios are expressed relative to sd-LDL increments of 10%. (Adjusted 1:
age, gender, current smoking, waist circumference; adjusted 2: age, gender,
current smoking, waist circumference, LDL cholesterol).
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Page 5 of 7the lumen, while 242 patients, who showed no or only
minimal signs of CAD on a subsequent angiographic
examination, served as controls. In accordance with our
study, the fraction of sdLDL was significantly higher in
the CAD group. In contrast to our data, however,
sdLDL remained a significant risk factor upon adjust-
ment for traditional risk factors, HDL cholesterol, and
LDL cholesterol. Kwon et al. used electrophoresis yield-
ing a size scale with a specific nanometre cut-off point
between small and large LDL particles, whereas our
measurements were based on density and a density cut-
off. Indeed, several reports, among those a systematic
review [23], emphasise the incongruence between
techniques.
Finally, Koz et al. [24] conducted a study in 102 con-
secutive young men with chest pain and a low Framing-
ham risk score. They all underwent a CAG. LDL size
was smaller in patients with CAD (n = 45), but it was
not a significant predictor upon adjustment for tradi-
tional risk factors. The results are therefore in good
agreement with ours. Moreover, the fact that the study
populations were quite dissimilar from ours (young men
performing military service vs elderly patients) empha-
sises the significance of the sdLDL parameter.
The alternative grouping of patients based on CT CAG
in our study in general showed a weaker correlation with
sdLDL, and its predictive value was lost after adjustment
for traditional risk parameters alone. This could in part
be explained by a reduced sample size, but it might also
reflect the fact that more participants in our study were
classified as having CAD on CT examination than on
invasive CAG. CT CAG is a fast emerging image modal-
ity, but the specificity of the method is suboptimal, and
this might readily explain the weaker correlation between
sdLDL and CT CAG-evaluated CAD.
The present study has some limitations. The sample
size was relatively small, and a priori patients belonged
to the low and intermediate CAD risk groups. Likewise,
the number of patients with significant stenoses was too
limited to enable us to graduate the extent rather than
the mere presence of CAD. Identifying patients with
CAD on the basis of significant stenoses may underesti-
mate the total number of patients with CAD, as visually
significant stenoses only represent patients with advanced
disease. Treatment with statins and b-adrenoceptor
antagonists is widespread in Denmark. Apart from a
reduction of LDL cholesterol and varying effect on other
lipid parameters dependent on the type of dyslipidemia
and the specific agent, statins have been shown to induce
a significant shift in the sdLDL subtype pattern towards
larger and more buoyant particles [25]. Thus, as a larger
percentage of the CAD group than of the no CAD group
received statins, the connection between sdLDL and
CAD may be even stronger than depicted here.
The findings of the present study provide further
support to the value of not only cholesterol in the
major lipoprotein subfractions (HDL and LDL), but
also the distribution and quality of particles within
each subfraction in risk assessment, as sdLDL, in con-
trast to LDL cholesterol, emerged as a univariate pre-
dictor of CAD. HDL cholesterol was, statistically, as
closely correlated to the CAD status, but the absolute
difference between the mean HDL values in the two
groups was small compared to the differences of
sdLDL. The study also demonstrates the clinical utility
of the iodixanol method which, in contrast to the
expensive NMR analysis, can be routinely incorporated
into clinical risk assessment. However, the widespread
use of statins makes it impossible to exclude patients
receiving this treatment and to generalize data to other
populations.
Conclusion
A significant difference in the proportion of sdLDL was
observed between patients with CAD and otherwise
highly similar patients without CAD. Clinical trials are
necessary to determine whether this is of importance for
stratification or patient outcome.
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